Multiinstitutional Phase 2 Clinical Trial of Intraoperative Molecular Imaging of Lung Cancer.

ABSTRACT:

Background

Intraoperative molecular imaging (IMI) may improve surgical outcomes during pulmonary resection for lung cancer. A multiinstitutional phase 2 IMI clinical trial was conducted using a near-infrared, folate receptor-targeted contrast agent for lung adenocarcinomas, OTL38. The primary goal was to determine whether OTL38 improved surgeons' ability to identify difficult to find nodules, occult cancers, and positive margins.

Methods

Patients with lung nodules received OTL38 (0.025 mg/kg) preoperatively. Patients had IMI sequentially during lung inspection, tumor resection, and margin check. Efficacy was evaluated by occurrence of clinically significant events, occurrences that caused the surgeon to modify the operation or upstage the patient's cancer. Safety was assesse

SUBMITTER: Gangadharan S 

PROVIDER: S-EPMC10985531 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature